Wire · opportunities
FDA OKs First Drug to Target Muscle Loss in Spinal Muscular Atrophy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
The FDA approved apitegromab-mstn (Isembyld) as the first therapy targeting muscle loss in spinal muscular atrophy (SMA), to be used alongside existing SMN2-targeted treatments in patients aged 2 and older. The approval is based on the phase 3 SAPPHIRE trial demonstrating improved motor function in nonambulatory type 2 or 3 SMA patients, with noted risks including fractures and hypersensitivity.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 12 Sep 2026 and 14 Sep 2026.
◆ ◆ The Wire takeaway
This FDA approval opens a new treatment avenue for Biotech founders focused on rare neuromuscular diseases by shifting market demand toward therapies improving muscle function beyond neuron survival. You should engage clinicians and patient groups now to position your muscle-targeting solutions as complementary or competitive.
◆ Coverage
9 sources · first reported 12 Sep 2026 · latest 14 Sep 2026
◆ Related on Wire
◆ Topics